Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Yesterday, the pharmaceutical company Amylyx announced that they are withdrawing the drug…
![Manténgase en [u]contacto[/u]](/paper-plane.svg)
Results of TUDCA-study: No effect of investigated compound
The TUDCA-ALS consortium has announced the first findings of the TUDCA study,…
Amylyx: no effect after analyzing phase 3 study
The pharmaceutical company Amylyx announced the first results of the PHOENIX study.…
Tofersen receives positive opinion from CHMP (EMA)
The Committe of Medicinal Products for Human Use (CHMP) of the European…
Results ADORE study: no effect of medication
The pharmaceutical company Ferrer has announced their first results of the ADORE…
34th International Symposium on ALS/MND
From 6 to 8 December 2023, more than 1300 people from all…
3FM Serious Request takes action for ALS Foundation Netherlands
3FM Serious Request is taking action for the ALS Foundation Netherlands during…
Over 200 patients participate in Lighthouse II study worldwide
The Lighthouse II study is a phase 3 clinical trial that compares…
ENCALS consensus statement on NurOwn
Background Given the interest around the use of stem cells in ALS,…
Apellis reports discontinuation of MERIDIAN study
Pharmaceutical company Apellis has announced the discontinuation of the open-label phase of…